SAN DIEGO, June 1, 2016 /PRNewswire/ --
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) has been approved by OTC Markets Group Inc. to uplist Regen’s Common and Series A Preferred shares to the OTCQB Venture Marketplace with an effective trading date of May 31, 2016. To be eligible to trade over the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process.
“We are excited about our uplist to the OTCQB for both our common and Series A Preferred stock. The management team believes trading our shares on the OTCQB provides strong evidence to shareholders of Regen’s commitment to transparency and full disclosure,” stated Regen’s Chairman & CEO David Koos.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company aims to rapidly advance these technologies through pre-clinical and Phase I/II clinical trials. Currently, the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Office
+1-619-702-1404 Phone
+1-619-330-2328 Fax
David.koos@regenbiopharma.com
http://www.regenbiopharma.com and
http://www.regenbiopharmainc.com
Twitter: Regen BioPharma News:
https://twitter.com/RegenBioPharm
The Dorsee Company
Debra Dorsee
+1-(858)-229-6082
Debbie@thedorseecompany.com
